Bezafibrate Trial in CPT2 Deficiency

Inclusion Criteria: * occurrence of at least 5 attacks of rhabdomyolysis or of severe myalgias per year, AND/OR permanent muscle weakness objectivized by muscle testing outside a rhabdomyolysis attack AND * significant decrease in both the CPT2 activity and the rate of long-chain fatty acid oxidation measured in lymphocytes and/or in a skeletal muscle sample outside a rhabdomyolysis attack Exclusion Criteria: * age below 18 years * less than 5 attacks of rhabdomyolysis or severe myalgias per year AND absence of muscle impairment detected by muscle testing * liver failure, renal failure, hyperhomocysteinemia prior to setting up the bezafibrate therapy * treatment with another hypolipidemic drug ("statins) or with anticoagulant * pregnancy or lactation during the period of fibrate therapy